Cipaglucosidase alfa + Miglustat
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II Infantile Onset
Conditions
Glycogen Storage Disease Type II Infantile Onset
Trial Timeline
Jul 18, 2023 → Jul 1, 2027
NCT ID
NCT04808505About Cipaglucosidase alfa + Miglustat
Cipaglucosidase alfa + Miglustat is a phase 3 stage product being developed by Amicus Therapeutics for Glycogen Storage Disease Type II Infantile Onset. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04808505. Target conditions include Glycogen Storage Disease Type II Infantile Onset.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04808505 | Phase 3 | Recruiting |
| NCT03911505 | Phase 3 | Active |
Competing Products
20 competing products in Glycogen Storage Disease Type II Infantile Onset